BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Jonathan DiVincenzo Joins Enzymatics Inc. as President and Chief Executive Officer


9/4/2012 9:57:35 AM

BEVERLY, Mass.--(BUSINESS WIRE)--Enzymatics, Inc., a rapidly growing provider of molecular biology reagents, today announced the appointment of Jonathan DiVincenzo as President and Chief Executive Officer. Mr. DiVincenzo brings more than 20 years of industry experience to the role having previously served as Corporate Officer of Millipore Corporation and President of its Bioscience Division. Mr. DiVincenzo joins Enzymatics to continue the growth fueled by the immense scientific skill set, drive and ambition of the Company’s workforce.

“Jon is a visionary leader with a strong track record of building global businesses serving the life science industry," said Ian Ratcliffe, Chairman of Enzymatics’ Board of Directors. "His experience and capabilities in bringing new technologies to global markets make him uniquely qualified to lead Enzymatics through its next wave of growth."

Enzymatics’ co-founders Stephen Picone and Christopher Benoit commented, “Enzymatics has evolved into a thriving business from a startup in 2007, growing to approximately 100 employees in just five years. We welcome Jon to the Enzymatics family, and with his extensive commercial and strategic experience, we will continue to build Enzymatics as the leading global supplier of high quality reagents and services to the rapidly expanding molecular genetics industry.” Stephen Picone and Chris Benoit are remaining at the Company in active roles under the new titles, Chief Strategy Officer and Chief Commercial Officer, respectively.

Mr. DiVincenzo has held several key leadership positions during his 18-year tenure at Millipore Corporation (now Merck Millipore). As the President of the Company’s Bioscience Division, Jon led 1200 employees and grew the division to over $600 million of revenues. Prior to that he served as Vice President of Global Sales and Service and as Vice President of Marketing and R&D. For several years, he also held senior marketing and product management positions within Millipore’s Lab Water business (which later became part of the Bioscience Division) in Paris. Before Millipore, Jon worked for Orion Research (now part of ThermoFisher Scientific) as Product Manager and Technical Support Engineer and for General Electric Corporation in thermodynamics engineering. Jon holds a Bachelor of Science degree in Mechanical Engineering from Northeastern University in Boston. He is a member of the Northeastern’s College of Engineering Advisory Board and Board of Directors of the Analytical and Life Science Systems Association (ALSSA).

About Enzymatics

Enzymatics is a leading provider of molecular biology reagents and manufacturing services that delivers unrivaled quality, consistency, and value to the commercial genomic sciences community. The company manufactures in the USA under ISO 13485 certification, is focused on building long-term partnerships, and leverages internal and external innovation to commercialize breakthrough technologies. www.enzymatics.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50394385&lang=en

Contacts

MacDougall Biomedical Communications, Inc.
Charles Liles or Doug MacDougall, 781-235-3060


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES